1. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol. 1998;38:389–430.
2. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283(3):1552–62.
3. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383–91.
4. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome-P-450 Hpcn3, a novel cytochrome-P-450 Iiia-gene product that is differentially expressed in adult human-liver - Cdna and deduced amino-acid sequence and distinct specificities of Cdna-expressed Hpcn1 and Hpcn3 for the metabolism of steroid-hormones and cyclosporineu. J Biol Chem. 1989;264(18):10388–95.
5. Huang WL, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004;32(12):1434–45.